Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ABNG vs NDRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NDRA Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 6–2 Matrix Metrics)

NDRA Overall Winner 6-Pillar Tally: ABNG 1 – 2 NDRA (3 Tie) Matrix Metrics: ABNG 2 – 6 NDRA

As of Nov 16, 2026, ENDRA Life Sciences Inc. (NDRA) is the stronger overall head-to-head candidate over ABNG (ABNG) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). ABNG carries a Unified Composite Score of 53.0/100 (HOLD) at $20.21 (N/M Forward P/E, N/A operating margin), whereas NDRA carries 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ABNG currently prints a higher short-term Unified Composite Score (53.0/100 HOLD vs. NDRA 44.7/100 HOLD), NDRA captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: ABNG trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 61.3); meanwhile NDRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABNG vs NDRA
ABNG US Equity
ABNG
Institutional Equity
$20.21
+8.39% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.34β · 71% Vol
Unified Composite Score
53.0 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.8% over 20 days), RSI 61
RSI-14: 61.3 · SMA20: $18.56 · SMA50: $17.34
NDRA NASDAQ Head-to-Head Winner
ENDRA Life Sciences Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.42
+0.23% 1D
Market Cap $6.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.71β · 48% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 35.0 Fund 46.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.3%), weak momentum, RSI 37
RSI-14: 36.7 · SMA20: $4.75 · SMA50: $5.32

6-Pillar Scorecard Institutional Category Breakdown (ABNG 1 – 2 NDRA)

Columns: Metric · ABNG · NDRA
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale NDRA
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A N/A
Market Cap N/A $6.6M
3. Profitability & Quality NDRA
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -152.0%
4. Balance Sheet & Cash Flow ABNG
Cash Generation (TTM) N/A -$8.0M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $104,744 Net Debt (0.26x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABNG (2) vs NDRA (6)
Institutional Metric ABNG NDRA Criterion Row Edge
Market Capitalization
Scale
N/A $6.6M Larger Scale NDRA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth NDRA
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin NDRA
Net Profit Margin
Profitability
N/A 0.0% Higher Margin NDRA
Return on Equity (ROE)
Capital Efficiency
N/A -152.0% Higher ROE NDRA
52-Week Range Position
Momentum
100% ($13–$20) 37% ($3–$7) Stronger Trend ABNG
Beta / 30D Volatility
Risk Regime
2.34β · 71% Vol 0.71β · 48% Vol Lower Realized Risk NDRA
Unified Institutional Score
Composite Signal
53.0 / 100 (HOLD) 44.7 / 100 (HOLD) Higher Composite ABNG
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$8.0M ($104,744 Net Debt (0.26x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABNG +19.35 pp
ABNG: +8.73% · NDRA: -10.62%
3M Horizon ABNG +19.05 pp
ABNG: +11.58% · NDRA: -7.47%
6M Horizon ABNG +15.04 pp
ABNG: +16.63% · NDRA: +1.59%
1Y Horizon ABNG +73.37 pp
ABNG: +45.31% · NDRA: -28.06%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABNG vs NDRA. Trailing 12-month operating profitability (ABNG N/A vs NDRA 0.0%) and valuation multiples (ABNG N/M vs NDRA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ABNG ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
NDRA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-152.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABNG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABNG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NDRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NDRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABNG Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NDRA Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $6.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABNG vs NDRA Key Questions & Quantitative Answers

As of Nov 16, 2026, ENDRA Life Sciences Inc. (NDRA) is the stronger overall head-to-head candidate over ABNG (ABNG) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). ABNG carries a Unified Composite Score of 53.0/100 (HOLD) at $20.21 (N/M Forward P/E, N/A operating margin), whereas NDRA carries 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ABNG currently prints a higher short-term Unified Composite Score (53.0/100 HOLD vs. NDRA 44.7/100 HOLD), NDRA captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: ABNG trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 61.3); meanwhile NDRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NDRA leads the Growth & Scale pillar: ABNG posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with NDRA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ABNG generates N/A in USD-normalized revenue versus N/A for NDRA. In operating R&D and SG&A reinvestment, ABNG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NDRA.

ABNG and NDRA trade at balanced relative valuation multiples. ABNG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas NDRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABNG (N/A ROE) versus NDRA (-152.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ABNG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.34β · 71% Vol realized risk). By comparison, NDRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 48% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.